NovaBay Pharmaceuticals (NBY) might move higher on growing optimism about its earnings prospects, which is reflected by its upgrade to a Zacks Rank #2 (Buy).
NovaBay Pharmaceuticals, Inc. (NYSE:NBY ) Q2 2024 Earnings Conference Call August 13, 2024 4:30 PM ET Company Participants Jody Cain - LHA, Investor Relations Justin Hall - Chief Executive Officer and General Counsel Tommy Law - Interim Chief Financial Officer Conference Call Participants Destiny Buch - Ladenburg Thalman Edward Woo - Ascendiant Capital Operator Good day, and welcome to the NovaBay Pharmaceuticals Second Quarter 2024 Financial Results Conference Call. All participants will be in listen-only mode.
NovaBay Pharmaceuticals (NYSEMKT: NBY ) stock is falling hard on Thursday after the eyecare and wound care company announced results from its annual shareholder meeting. Included among the proposals in the annual shareholder meeting was a reverse stock split.
| Biotechnology Industry | Healthcare Sector | Michael Kazley CEO | AMEX Exchange | 66987P201 CUSIP |
| US Country | 13 Employees | 30 Sep 2025 Last Dividend | 31 May 2024 Last Split | - IPO Date |
NovaBay Pharmaceuticals, Inc. is a healthcare company engaged in the development and commercialization of eyecare and wound care products across the United States and internationally. Known for its innovative approach towards effective healthcare solutions, the company provides a range of products targeted at improving ocular health and managing wounds. Initially named NovaCal Pharmaceuticals, Inc., it underwent a name change to NovaBay Pharmaceuticals, Inc. in February 2007. Since its incorporation in 2000, the company has been dedicated to offering products that meet the needs of patients, leveraging advanced technology and research to create effective solutions. Headquartered in Emeryville, California, NovaBay Pharmaceuticals continues to expand its portfolio and market presence, reaching a broader audience through both its web stores and various third-party online retailers and distribution partners.